Health · 41 views
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 41 Community interest
Brief read Under 1 min brief 26 words
Summary
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Rise in NHS birth centre closures ‘shocking’ denial of women’s rights, experts sayContinue reading
- Retatrutide Is One Click Away. That Doesn't Make it Safe.Continue reading
- Normal-looking sleep can mask memory problems, study suggestsContinue reading
- Study Finds Evidence of Cannabis Use 2,800 Years AgoContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow